Secondary analysis of the phase III A-BRAVE trial (466 high-risk early TNBC; TILs in 387): adjuvant avelumab vs observation benefited only those with baseline TILs ≥30%, notably after neoadjuvant chemo (3-year DDFS 92% vs 58.7%, HR 0.20; interaction P=0.019).
Secondary analysisn = 466
Dieci et al. Tumor-Infiltrating Lymphocytes as a Predictor of Adjuvant Avelumab Efficacy in Patients with High-risk Triple-Negative Breast Cancer